Bivalent Human Papilloma Virus Vaccine (Cervarix) in the treatment of cutaneous warts

Ibrahim, Samia Ali; Hamed, Shima Maher; Ibrahim, Howyda Mohamed; Morsi, Hala Mohamed

doi:10.21608/zumj.2021.91611.2321

Bivalent Human Papilloma Virus Vaccine (Cervarix) in the treatment of cutaneous warts

Document Type : Original Article

Authors

¹ Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

² zagazig general Hospital

³ Zagazig University Hospital

⁴ dermatology &amp;venereology department, faculty of medicine, Zagazig university

10.21608/zumj.2021.91611.2321

Abstract

Abstract
Background
Bivalent human papilloma virus (HPV) vaccine has a successful effect in therapy of recalcitrant cutaneous warts.
Objective
The purpose of this study is to assess the efficacy and safety of intralesional (IL) injection of bivalent HPV vaccine (cervarix) versus IL saline in therapy of recalcitrant cutaneous warts.
Patients and Methods
Forty-four patients with resistant warts to therapy were classified into 2 groups; 22 patients in each group. Group A was received Cervarix vaccine 0.1ml into the biggest wart 2-weeks apart and group B (control) was received IL saline. The patients in both groups received sessions until the patients achieved complete clearance or for a five sessions.
Results
One month after the treatment, 86.4% of patients achieved complete response in group A (IL cervarix vaccine) versus to 4.2 % of the control (group B) with a highly significant difference (P

Keywords

Main Subjects